As shown in Table 14.1, both technologies do not use enzymes for target amplification, thus there is less concern of contamination and enzyme inhibition. Both technologies use the dioxetane chemiluminescent method for detection. No DNA or RNA extraction is needed in both technologies. Microwell plate immunoassay-like format can be performed in one room and by semiautomated systems, making both technologies easy to be implemented in the clinical laboratory setting.
The difference is that many synthetic oligonucleotides (probes) are used in bDNA for signal amplification and two anti-RNA:DNA hybrid antibodies are used in HC2 for signal amplification. The bDNA technology is mainly used for quantitative analysis of viruses such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV). The HC2 technology is mainly used for qualitative detection of viral or bacterial infection, with the exception of hepatitis B virus (HBV) and cytomegalovirus (CMV).
Was this article helpful?